ADJUTEC PHARMA AS: årsregnskap 2022 vs 2021
Grew 124829% on revenue, weaker earnings, fresh owner capital
approved 2023-04-13; registry 2023-06-03; journal 2023 419250
Summary
What changed
Comparing Årsregnskap 2022 with 2021 for ADJUTEC PHARMA AS. Revenue 6 277 NOK → 7.84m NOK (+124828.7%). Net result -3.52m NOK → -17.15m NOK. Equity 32.76m NOK → 27.60m NOK.
On the constructive side: revenue rose; cash rose; owners injected capital. Pressures included: operating result weakened; net result weakened; equity eroded.
Also worth watching: headcount (årsverk) changed. All figures are taken from the published annual accounts for ADJUTEC PHARMA AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 6 277 NOK to 7.84m NOK (+124828.7% YoY). Calculated
-
↑
Cash rose
Bank deposits 23.85m NOK → 25.64m NOK (+7.5% YoY). Calculated
-
↑
Owners injected capital
Paid-in equity rose 37.02m NOK → 49.02m NOK (+11.99m NOK). Reported fact
What deteriorated
-
↓
Operating result weakened
Operating result -5.22m NOK → -23.40m NOK (op. margin -83090.0% → -298.3%). Calculated
-
↓
Net result weakened
Net result -3.52m NOK → -17.15m NOK (net margin -56013.5% → -218.7%). Calculated
-
↓
Equity eroded
Book equity 32.76m NOK → 27.60m NOK (equity ratio 99.3% → 81.2%). Calculated
Things to notice
-
·
Headcount (årsverk) changed
Reported FTEs 1 → 5. Reported fact